Alessandra Moroni

Recent experience includes advising on investment screening and trade controls in the following matters:

• Gallagher in the investment screening, subsidy control and sanctions compliance aspects of its US$13.45 Billion acquisition of AssuredPartners.
  
• Rivean Capital in the investment screening and subsidy control aspects of the acquisition of Perbility GmbH.
• Siris Capital Group in the investment screening aspects of its US$591 million Sale of Fiery.
• Clearlake Capital in the investment screening aspects of its Strategic Investment in Aptean.
• Funds managed by affiliates of Apollo Global Management, Inc. in the subsidy control aspects acquisition of The Travel Corporation.
• Clearlake Capital and Francisco Partners in the investment screening and trade controls aspects of their US$2.1 billion acquisition of Software Integrity Group.
• Funds managed by affiliates of Apollo Global Management, Inc. in the investment screening and subsidy control aspects of their minority equity investment in AUTODOC SE.
• One Equity Partners and Buckthorn Partners in the investment screening and subsidy control aspects of their acquisition of Acteon Group.
• Allkem in the investment screening and trade controls aspects of its US$10.6 billion merger of Equals with Livent.
• Regal Rexnord in the investment screening and trade controls aspects of its US$4.95 billion acquisition of Altra Industrial Motion.
• Crown Bioscience in the investment screening and trade controls aspects of its acquisition of the IndivuServ business unit of Indivumed GmbH.
• Clearlake Capital Group, L.P. in the investment screening and trade controls aspects of its US$1.875 billion sale of Brightly Software, a cloud-based asset management software platform, to Siemens.
• Clearlake Capital Group, L.P. in its acquisition of Chelsea Football Club and related affiliates in a consortium co-led with Todd Boehly, Chairman and CEO of Eldridge, in particular advising on sanctions risks and mitigating measures. The acquisition was named “Private Equity Deal of the Year” at The Deal Awards 2022.
• Newfold Digital in the investment screening and trade controls aspects of its acquisition of YITH, an independent seller and developer of WooCommerce plugins and themes for WordPress, a free and open-source content management system.
• KKR in the investment screening and trade controls aspects of its majority acquisition of Biosynth Carbosynth, a Swiss life sciences reagents and custom synthesis and manufacturing services company.
• Confluence Technologies, Inc. in the investment screening and trade controls aspects of its US$500 million acquisition of Investment Metrics, a major provider of investment data, performance, analytics, and research software solutions.
• Affiliates in the investment screening and trade controls aspects of WCAS and Managed Market Insights & Technology in connection with MMIT’s US$1.6 billion merger with Evaluate.
• Magna International Inc. in the investment screening and trade controls aspects of its US$3.8 billion acquisition of Veoneer, Inc., a provider of state-of-the-art software, hardware, and systems for occupant protection, ADAS, and collaborative and automated driving to OEMs globally.
• Clearlake Capital Group, L.P. in the investment screening and trade controls aspects of its proposed US$5.2 billion acquisition of Cornerstone OnDemand, Inc., a global leader in talent management software.
• Clearlake Capital in the investment screening and trade controls aspects of its significant equity investment in RSA Security LLC, a global provider of mission critical cybersecurity software and governance risk and compliance management software.
• KKR in the investment screening and trade controls aspects of its investment in Nordic Bioscience, a Danish biomarker development company.
• Clearlake Capital Group, L.P. in the investment screening and trade controls aspects of its acquisition of Precisely together with TA Associates.
• Cubic Corporation in the investment screening and trade controls aspects of its acquisition by Veritas Capital and Evergreen Coast Capital for an enterprise value of US$2.8 billion.
• Arvelle Therapeutics, a Swiss-based biopharmaceutical company, in the investment screening and trade controls aspects of its sale to Angelini Pharma for a total cash consideration of up to US$960 million.

Alessandra provides pro bono assistance through Sidley’s Trade for Development Initiative and Emerging Enterprises Pro Bono Program, which provides free legal and technical advice to least developed and low-income developing countries, trade associations, small- and medium-size for-profit enterprises, and market-focused, non-governmental organizations in areas related to trade, investment, and relevant regulations.

For instance, as part of Sidley’s Trade for Development Initiative, Alessandra advised Bangladesh Garment Manufacturers and Exporters Association (BGMEA) on preserving preferential access to the EU market via the EU Generalized Scheme of Preferences (GSP).